董占飞, 秦永德, 王新华. 89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察[J]. 中国肿瘤临床, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024
引用本文: 董占飞, 秦永德, 王新华. 89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察[J]. 中国肿瘤临床, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024
shu
Zhanfei DONG, Yongde QIN, Xinhua WANG. Clinical Observation of Internal Radiotherapy using 89Sr 99Tc-MDP and Zoledronic Acid in the Treatment and Pain Relief of Lung Cancer Patients with Bone Metastasis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024
Citation: Zhanfei DONG, Yongde QIN, Xinhua WANG. Clinical Observation of Internal Radiotherapy using 89Sr 99Tc-MDP and Zoledronic Acid in the Treatment and Pain Relief of Lung Cancer Patients with Bone Metastasis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(21): 1660-1662. DOI: 10.3969/j.issn.1000-8179.2012.21.024
shu

89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察

Clinical Observation of Internal Radiotherapy using 89Sr 99Tc-MDP and Zoledronic Acid in the Treatment and Pain Relief of Lung Cancer Patients with Bone Metastasis

    摘要
  • 摘要:
      目的  观察89SrCl2、89Sr联合99Tc-MDP、89Sr联合唑来膦酸治疗肺癌骨转移的疗效。
      方法  95例肺癌骨转移患者随机分为对照组(33例)与试验组A(30例)、试验组B(32例), 分别用89Sr治疗、89Sr联合99Tc-MDP治疗, 89Sr联合唑来膦酸治疗。主要观察三组患者治疗前后的疼痛、生活质量、血象、骨显像所示骨转移灶数目的改善情况。计数资料采用卡方检验, 计量资料采用均数t检验。
      结果  对照组、试验组A、试验组B骨痛缓解有效率分别为57.58%、83.33%、81.25%。经统计分析, 试验组A、B与对照组骨痛缓解有效率、全身状况Karnofsky评分提高率(51.52%、80.00%、71.88%)、骨转移病灶治疗有效率(60.61%、83.33%、84.38%), 三组间有效率差异有统计学意义(P均 < 0.05), 而不良反应试验组无明显增加(χ2=1.885, P > 0.05)。
      结论  89Sr联合99Tc-MDP、89Sr联合唑来膦酸的治疗方法较单独使用89Sr均能显著提高缓解疼痛的临床疗效。

     

    Abstract:
      Objective  To evaluate the palliative effect on pain relief in lung cancer patients with bone metastasis treated with 89Sr and 99Tc-MDP, 89Sr and zoledronic acid, and 89Sr alone.
      Methods  Ninety-five lung cancer patients with bone metastasis were randomly divided into experimental groups A, B, and the control. The control group (33 patients), group A (30 patients), and group B (32 patients) were treated with 89Sr only, 89Sr combined with 99Tc-MDP, and 89Sr combined with zoledronic acid, respectively. Improvements in pain, quality of life, blood routine, and the number of bone metastases were mainly observed before and after treatment.χ2 test was performed to analyze data.
      Results  The overall palliative pain relief rates in the experimental treatment groups A and B were 81.25% and 83.33%, respectively. For the control group, the palliative pain relief rate was 57.58%. Statistically significant differences in the overall palliative pain relief rate (χ2=6.801) were observed among groups A, B, and the control with single-treatment modalities. Significant dif-ferences were also observed in the improvement of the whole-body Kamofsky performance status score (51.52%, 80.00%, and 71.88%; χ2=6.246) and focal palliative rate (60.61%, 83.33% and 84.38%; χ2=6.362). Side effects did not increase significantly (χ2=1.885, P> 0.05).
      Conclusion  The combined treatments of 89Sr and 99Tc-MDP as well as 89Sr and zoledronic acid are more effective than the single-treatment modalities in bone pain relief associated with bone metastasis. These combinations can significantly improve the efficacy of the treatment of bone metastasis in lung cancer patients.

     

    • HTML全文
    • 参考文献(9)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回